AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
25 Jul 2019 07:00 AM
RNS
AZN: H1 2019 Results
15 Jul 2019 07:00 AM
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 07:00 AM
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 03:00 PM
RNS
Total Voting Rights
01 Jul 2019 07:00 AM
RNS
Fasenra receives positive EU CHMP opinion for self
01 Jul 2019 07:00 AM
RNS
Forxiga receives positive EU CHMP opinion for
27 Jun 2019 07:00 AM
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 07:00 AM
RNS
Breztri Aerosphere (PT010) approved in Japan for
19 Jun 2019 07:00 AM
RNS
Bevespi Aerosphere approved by the Japanese
19 Jun 2019 07:00 AM
RNS
Lynparza approved in Japan for 1st-line
18 Jun 2019 07:00 AM
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 07:00 AM
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 04:45 PM
RNS
Publication of a Prospectus
06 Jun 2019 07:00 AM
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 PM
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 03:00 PM
RNS
Block listing Interim Review
03 Jun 2019 03:00 PM
RNS
Total Voting Rights
03 Jun 2019 07:00 AM
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 07:00 AM
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2019 11:00 AM
RNS
Director Declaration
08 May 2019 07:00 AM
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 07:00 AM
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 07:00 AM
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 03:00 PM
RNS
Total Voting Rights
01 May 2019 12:00 PM
RNS
Director/PDMR Shareholding
29 Apr 2019 07:00 AM
RNS
Lynparza receives positive EU CHMP opinion for 1st
26 Apr 2019 05:45 PM
RNS
Result of AGM
26 Apr 2019 07:00 AM
RNS
AZN: Q1 2019 Results
10 Apr 2019 07:00 AM
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 04:10 PM
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 01:30 PM
RNS
Holding(s) in Company
03 Apr 2019 10:00 AM
RNS
Director/PDMR Shareholding
02 Apr 2019 03:00 PM
RNS
Total Voting Rights
01 Apr 2019 03:00 PM
RNS
Total Voting Rights
01 Apr 2019 07:00 AM
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 05:15 PM
RNS
Results of Placing
29 Mar 2019 07:00 AM
RNS
Proposed placing of new ordinary shares
29 Mar 2019 07:00 AM
RNS
AZ and Daiichi Sankyo enter collaboration in novel
27 Mar 2019 07:00 AM
RNS
Forxiga approved in Japan for type-1 diabetes
25 Mar 2019 07:00 AM
RNS
Forxiga approved in Europe for type-1 diabetes
18 Mar 2019 07:00 AM
RNS
US FDA grants saracatinib ODD for IPF
14 Mar 2019 12:00 PM
RNS
Notice of AGM
12 Mar 2019 12:00 PM
RNS
Director/PDMR Shareholding
06 Mar 2019 07:00 AM
RNS
Filing of Form 20-F with SEC
05 Mar 2019 11:00 AM
RNS
Annual Financial Report
01 Mar 2019 03:00 PM
RNS
Total Voting Rights
01 Mar 2019 01:45 PM
RNS
Lynparza receives positive EU CHMP opinion
26 Feb 2019 07:00 AM
RNS
Lynparza significantly delayed disease progression
25 Feb 2019 07:00 AM
RNS
Brilinta's PhIII THEMIS trial met primary endpoint
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings